Golimumab - a new tool in the armoury against inflammatory arthritis. - Wikidata - wikimedia - TriplyDB

Golimumab - a new tool in the armoury against inflammatory arthritis.

Golimumab - a new tool in the armoury against inflammatory arthritis.

http://www.wikidata.org/entity/Q37829741

about

Golimumab as rescue therapy for refractory immune-mediated uveitis: a three-center experience.Biologic therapy for autoimmune diseases: an update.Tumor necrosis factor inhibitors in psoriatic arthritis.Golimumab for the treatment of refractory juvenile idiopathic arthritis-associated uveitis.Twelve years' experience with etanercept in the treatment of rheumatoid arthritis: how it has changed clinical practice.

P2860

Q33757440-4280F7A8-2617-4FE5-AB74-B81A224A8DC1 Q34655597-D4141D74-6D7C-4879-A765-FFA9A59EF791 Q38685543-82444F29-E6BE-49FB-8AB7-FE126BE5EE8E Q41457227-9DBC52D6-D706-4CA5-8046-89F96F60B2D2 Q53650686-09C329A2-4CCE-4FB2-BED0-C18CDA63C7DB

P2860

Golimumab - a new tool in the armoury against inflammatory arthritis.

http://www.wikidata.org/entity/Q37829741

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 18 January 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Golimumab - a new tool in the armoury against inflammatory arthritis.

@en

Golimumab - a new tool in the armoury against inflammatory arthritis.

@en-gb

Golimumab - a new tool in the armoury against inflammatory arthritis.

@nl

type

label

Golimumab - a new tool in the armoury against inflammatory arthritis.

@en

Golimumab - a new tool in the armoury against inflammatory arthritis.

@en-gb

Golimumab - a new tool in the armoury against inflammatory arthritis.

@nl

prefLabel

Golimumab - a new tool in the armoury against inflammatory arthritis.

@en

Golimumab - a new tool in the armoury against inflammatory arthritis.

@en-gb

Golimumab - a new tool in the armoury against inflammatory arthritis.

@nl

P1433

Q37829741-B70715C9-50C4-4DCE-AC38-87781422C781

P1476

Q37829741-A28BC9DB-CF3E-44E6-BEDD-CF916B26A289

P2093

Q37829741-A16A77AF-0F85-42E1-9E2F-9FB85B0E9A7D

P2860

Q37829741-0ABC340F-81A1-4637-85F7-52A078FFA70C

Q37829741-19040AB0-F533-4DFE-A14D-BFDF81EC7B61

Q37829741-220244C1-E3F2-4742-8DEE-9B5A2EE76DBC

Q37829741-2E494C37-B478-42FF-9460-B972CF97A0E3

Q37829741-33AC3F27-125E-40B5-81A0-3E299A68E845

Q37829741-3BA7C50E-EF60-4943-9C8E-65AA8267D1DC

Q37829741-3CDBC5E4-49F8-4CEC-B2E3-EC07D8C44B9A

Q37829741-56F94F18-0C71-4646-BB1E-BEC73E2EFAFB

Q37829741-58D13ACD-6388-4F3B-8307-B9B9C1FC0C56

Q37829741-6A321577-DB5F-4C7B-B0E3-69FCEC220FB3

P304

Q37829741-4DE310C5-FC9D-4EB4-BDFE-C552C410A401

P31

Q37829741-A1935127-0DAC-4492-AA85-2011C201CA4A

P356

Q37829741-1D09DF71-9C88-4F8D-9A5B-5B87E8E1A528

P407

Q37829741-09DA4ADD-85F3-45D2-B68F-E41DC30C3344

P433

Q37829741-28468BD9-9764-4921-A426-CBFEA0C747A3

P478

Q37829741-EE96D77C-6879-49EA-9B0E-D196F920C592

P50

Q37829741-70430C23-C916-419E-B321-8860090EF0A7

P577

Q37829741-E4177151-A101-472C-B864-20028DF9E99B

P6179

Q37829741-364FB93C-E253-4777-92C7-5B9B66B44ED9

P698

Q37829741-0FCF827A-B6DA-499B-B1AA-79E70754A97F

P921

Q37829741-F4BA6FC5-261F-40C1-97B8-67F672111DD6

P356

07853890.2010.549148

P1433

Annals of Medicine

P1476

Golimumab - a new tool in the armoury against inflammatory arthritis.

@en

P2093

Zoe Ash

http://www.w3.org/2001/XMLSchema#string

P2860

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-cont

Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial.

Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis.

Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study.

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.

Subcutaneous bioavailability of golimumab at 3 different injection sites in healthy subjects.

Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study.

Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial.

Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists.

Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas.

P304

133-141

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/07853890.2010.549148

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

43

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-01-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1037132555

http://www.w3.org/2001/XMLSchema#string

P698

21244218

http://www.w3.org/2001/XMLSchema#string

P921